Drug Development Solutions

ADME and toxicity - the major problems in drug development today

Recent statistics have shown that only 30% of candidate compounds fail to become drugs due to lack of efficacy, whereas over 60% fail due to problems with Adsorption, Distribution, Metabolism, Excretion and Toxicology (ADMET). This is the fundamental cause of the current high attrition rates in drug development.

CXR offer a range of mechanism based solutions to identify ADMET liabilities of compounds early in discovery to reduce the attrition rates in drug development.

Mechanism based Solutions :

'Hits to optimised leads' more....

CXR Biosciences employ cutting edge genomic, bioinformatic, and molecular biology expertise to design and develop novel methodologies and technologies that accurately predict the ADMET characteristics of compounds early in drug discovery, enabling lead compound selection to be based on both pharmacological efficacy and ADMET properties. As lead compounds selected in this manner are more ‘drug-like’, it reduces the risk of failure, and ensures resources are concentrated on the most promising drug candidates, thus reducing the attrition rate in later drug development.

Novel preclinical models more....

CXR Biosciences is continually developing novel models for preclinical development that are more rapid, more informative and more relevant to man than existing approaches. Using a combination of molecular biology, transgenic, and bioinformatic expertise, CXR have developed exceptional models that enable unique mechanistic information about drug metabolism and toxicity to be determined in vivo. These models enable CXR to quickly identify any ADME or toxicity issues in vivo early in drug discovery in a single screen thus saving time and expense.

Customised assay development more....

CXR Biosciences can rapidly design and develop innovative new assays and screens tailored specifically to the client's requirements. These bespoke assays provide drug developers with unique insights into the mechanisms of efficacy and/or toxicity of compounds to enable more informed lead selection and preclinical development.

Late stage product rescue more....

CXR Biosciences can rescue drug candidates that encounter unexpected efficacy or toxicity problems in late stage preclinical safety studies or in phase 1 clinical studies. By investigating and understanding the underlying toxic or metabolic mechanisms, CXR can determine the relevance to man of observations made in animal models, or alternatively devise clinical strategies to overcome efficacy limitations.

Lab based 'Due Diligence'  more....

CXR Biosciences can lower the risk of late stage failure of in licenced compounds by more accurately determining the ADME / Tox liabilities of compounds prior to signing a licencing deal. Our expert review of the accompanying data package will quickly identify ADME/Tox data gaps, and we can rapidly provide experimental evidence to fill those gaps thereby providing more comprehensive information on which to base a licensing decision.